Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
To investigate the functional role of NCAM1 in pediatric acute megakaryoblastic leukemia (AMKL) associated with the CBFA2T3-GLIS2 gene fusion
FY 2020-21
Summary
Acute megakaryoblastic leukemia (AMKL), a subtype of acute myeloid leukemia (AML), is a pediatric disease affecting infants and children less than 3 years old. This rare subtype of leukemia is commonly associated with genetic mutations and fusions that worsen survival rates, increase risk of early relapse and increase resistance to chemotherapies. We have generated human models of AMKL carrying these genetic lesions in our laboratory using genetic modification techniques in human cord blood cells and transplantation into immunodeficient mice. The goal of my project is to study a biomarker that is associated with adverse outcomes and has previously been identified in high risk AMLs called NCAM1 to determine its role in sustaining AMKL disease. Using our models, we hope to better understand which subpopulation of cells express NCAM1 and its functional role in AMKL. These findings will further our understanding and contribute to the development of tailored therapies using NCAM1 as a target in hard to treat high risk AML subtypes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449324
Name
Cheetham Emma R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
To investigate the functional role of NCAM1 in pediatric acute megakaryoblastic leukemia (AMKL) associated with the CBFA2T3-GLIS2 gene fusion
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Megakaryoblastic Leukemia; Cbfa2t3-Glis2 Fusion; Cell Lines; Dose Response Analyses; Functional Assays; Gene Expression; Human Cord Blood; Knockdown; Neural Cell Adhesion Molecule 1; Xenograft Models
Abstract
Acute megakaryoblastic leukemia (AMKL), a subtype of acute myeloid leukemia (AML), is a pediatric disease affecting infants and children less than 3 years old. This rare subtype of leukemia is commonly associated with genetic mutations and fusions that worsen survival rates, increase risk of early relapse and increase resistance to chemotherapies. We have generated human models of AMKL carrying these genetic lesions in our laboratory using genetic modification techniques in human cord blood cells and transplantation into immunodeficient mice. The goal of my project is to study a biomarker that is associated with adverse outcomes and has previously been identified in high risk AMLs called NCAM1 to determine its role in sustaining AMKL disease. Using our models, we hope to better understand which subpopulation of cells express NCAM1 and its functional role in AMKL. These findings will further our understanding and contribute to the development of tailored therapies using NCAM1 as a target in hard to treat high risk AML subtypes.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheetham, Emma R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~